However, molecular profiling of breast cancer is expensive and not routinely available in breast pathology, and instead, immunohistochemical assessment of ER, PR, HER2 and Ki67 is used for surrogate subtype classification of the intrinsic molecular subtypes [5, 9, 14, 15]. This evidence concerns the gene ERBB2 and breast carcinoma.